While triple-negative breast cancer (TNBC), which lacks ER, PR, and HER-2 expression, is known for its aggressive clinical course, the majority of experimental validation in this study was conducted on MCF-7 cells, which are estrogen receptor-positive (ER+) (11–13). Here, ESR1 is linked to triple-negative breast carcinoma.